journal article·2016-11-09

Vitamin B6 Tethered Endosomal pH Responsive Lipid Nanoparticles for Triggered Intracellular Release of Doxorubicin

Shweta Sharma, Ashwni Verma, Jyotsana Singh, B. Venkatesh Teja, Naresh Mittapelly, Gitu Pandey, Sandeep Urandur, Ravi P. Shukla, Rituraj Konwar, Prabhat Ranjan Mishra

Publisher page

Abstract

This study reports the development of Vitamin B6 (VitB6) modified pH sensitive charge reversal nanoparticles for efficient intracellular delivery of Doxorubicin (DOX). Herein, VitB6 was conjugated to stearic acid, and the nanoparticles of the lipid were formulated by solvent injection method (DOX-B6-SA-NP). Because of the p K a (5.6) of VitB6, DOX-B6-SA-NP showed positive charge and enhanced release of DOX at pH 5. Confocal microscopy illustrated that DOX-B6-SA-NP treatment kept higher DOX accumulation inside the cells than conventional pH insensitive lipid nanoparticles (DOX-SA-NP). The cationic charge of nanoparticles subsequently facilitated the endosomal escape and promoted the nuclear accumulation of DOX. Furthermore, in vitro cytotoxicity, apoptosis, cell cycle arrest, and mitochondrial membrane depolarization studies supported the enhanced efficacy of DOX-B6-SA-NP in comparison to free DOX and DOX-SA-NP. Intravenous pharmacokinetics and biodistribution investigations indicated that pH sensitive nanoparticles can significantly prolong the blood circulation time of DOX in biological system and increase the drug accumulation to tumor site. Consequent to this, DOX-B6-SA-NP also exhibited much enhanced therapeutic efficacy and lower toxicity in tumor-bearing rats compared to free DOX. The reduction in toxicity was confirmed by histological and survival analysis. In conclusion, these results suggest that the VitB6 modified charge reversal nanoparticles can be a novel platform for the successful delivery of anticancer drugs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Radiation Therapy and Dosimetry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Academy of Scientific and Innovative Research, New Delhi, Delhi 110020, India

Funding

Council of Scientific and Industrial Research

References (52)

Show source-provided references
1. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
2. 10.1016/j.colsurfb.2015.05.01410.1016/j.colsurfb.2015.05.014 ↗
3. 10.1016/S0168-3659(01)00281-410.1016/S0168-3659(01)00281-4 ↗
4. 10.1021/nl047998710.1021/nl0479987 ↗
5. 10.1021/ja410828710.1021/ja4108287 ↗
6. 10.1021/nn101670k10.1021/nn101670k ↗
7. 10.1039/C4RA14368J10.1039/C4RA14368J ↗
8. 10.1016/j.biomaterials.2014.01.01810.1016/j.biomaterials.2014.01.018 ↗
9. 10.1517/17425247.2013.82197810.1517/17425247.2013.821978 ↗
10. 10.1021/ja207150n10.1021/ja207150n ↗
11. 10.1016/j.ajps.2013.07.02110.1016/j.ajps.2013.07.021 ↗
12. 10.1021/ja800086u10.1021/ja800086u ↗
13. 10.1021/mp400787s10.1021/mp400787s ↗
14. 10.1016/j.apsb.2016.05.01110.1016/j.apsb.2016.05.011 ↗
15. 10.1016/j.jconrel.2010.01.03610.1016/j.jconrel.2010.01.036 ↗
16. Scheffel U. · J. Nucl. Med. · 1972 · 13 · 498
17. 10.1039/C5DT03412D10.1039/C5DT03412D ↗
18. 10.1016/j.biomaterials.2013.01.09810.1016/j.biomaterials.2013.01.098 ↗
19. 10.1021/bc00028a00510.1021/bc00028a005 ↗
20. 10.3892/etm.2011.23810.3892/etm.2011.238 ↗
21. 10.1073/pnas.070307110410.1073/pnas.0703071104 ↗
22. 10.2147/DDDT.S5817810.2147/DDDT.S58178 ↗
23. 10.1016/j.scient.2011.05.00610.1016/j.scient.2011.05.006 ↗
24. 10.1039/C5RA22224A10.1039/C5RA22224A ↗
25. 10.4103/2230-973X.13304710.4103/2230-973X.133047 ↗
26. 10.1186/s12951-015-0082-810.1186/s12951-015-0082-8 ↗
27. 10.1016/j.actbio.2015.12.01710.1016/j.actbio.2015.12.017 ↗
28. 10.1016/j.actbio.2015.08.00510.1016/j.actbio.2015.08.005 ↗
29. 10.1038/nprot.2006.23810.1038/nprot.2006.238 ↗
30. 10.1039/C5CC04035C10.1039/C5CC04035C ↗
31. 10.1016/j.nano.2015.12.38310.1016/j.nano.2015.12.383 ↗
32. 10.1021/nl080561510.1021/nl0805615 ↗
33. 10.1016/j.drudis.2006.07.00510.1016/j.drudis.2006.07.005 ↗
34. 10.1039/c1py00360g10.1039/c1py00360g ↗
35. 10.4155/tde.11.14610.4155/tde.11.146 ↗
36. 10.1002/adma.20120229610.1002/adma.201202296 ↗
37. 10.1002/adfm.20090082510.1002/adfm.200900825 ↗
38. 10.1002/ange.20080096310.1002/ange.200800963 ↗
39. 10.1016/j.biomaterials.2015.05.02010.1016/j.biomaterials.2015.05.020 ↗
40. 10.1039/c2sm07452d10.1039/c2sm07452d ↗
41. 10.1039/C5BM00479A10.1039/C5BM00479A ↗
42. 10.1002/adfm.20120131610.1002/adfm.201201316 ↗
43. 10.1038/nature1201410.1038/nature12014 ↗
44. 10.1016/j.jconrel.2006.02.01410.1016/j.jconrel.2006.02.014 ↗
45. 10.1021/acs.biomac.5b0103910.1021/acs.biomac.5b01039 ↗
46. Koutsilieris M. · Mol. Med. · 1999 · 5 · 8610.1007/BF03402143 ↗
47. 10.5507/bp.2004.02910.5507/bp.2004.029 ↗
48. 10.1016/j.ejpb.2012.03.00910.1016/j.ejpb.2012.03.009 ↗
49. 10.1039/C5NR05264E10.1039/C5NR05264E ↗
50. 10.1016/j.ijpharm.2008.09.02210.1016/j.ijpharm.2008.09.022 ↗
51. 10.1016/j.ijpharm.2007.12.01610.1016/j.ijpharm.2007.12.016 ↗
52. 10.1208/s12248-012-9339-410.1208/s12248-012-9339-4 ↗